Furobufen
(Synonyms: 呋罗布芬) 目录号 : GC60171
Furobufen 是一种抗炎药，可产生抗关节炎，解热作用。Furobufen 对发炎的组织有镇痛作用。
Cas No.:38873-55-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Furobufen, an anti-inflammatory agent, produces antiarthritic, antipyretic effects. Furobufen has an analgesic effect in inflamed tissue[1].
Furobufen (po; 10, 30, 90 mg/kg; once daily; 7 days) produces a dose-related inhibition of the paw edema produced by carrageenan in male rats weighing 180-200 g[1].
[1]. Martel RR, et al. Anti-inflammatory properties of furobufen. Can J Physiol Pharmacol. 1974 Jun;52(3):669-73.
| Cas No. | 38873-55-1 | SDF | |
| 别名 | 呋罗布芬 | ||
| Canonical SMILES | OC(CCC(C1=CC2=C(C=C1)OC3=CC=CC=C23)=O)=O | ||
| 分子式 | C16H12O4 | 分子量 | 268.26 |
| 溶解度 | DMSO: 100 mg/mL (372.77 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7277 mL | 18.6386 mL | 37.2773 mL |
| 5 mM | 0.7455 mL | 3.7277 mL | 7.4555 mL |
| 10 mM | 0.3728 mL | 1.8639 mL | 3.7277 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Disposition of Furobufen in mice, rats, dogs, and man
Drug Metab Dispos 1981 Mar-Apr;9(2):119-24.PMID:6113109doi
Upon administration of the nonsteroidal anti-inflammatory agent Furobufen to mice, rats, dogs, and man, 2-dibenzofuranacetic acid (DBFA) was rapidly formed and was the major circulating metabolite. There was a species difference in the rate of DBFA formation; the serum elimination half-lives (t1/2) of Furobufen and DBFA were 25 min and 6 hr in rats, 35 min and 15 hr in dogs, and 3 hr and approximately 20 hr in man, respectively. After oral and intravenous administration of 14C-furobufen to rats and dogs, virtually all of the serum radioactivity was due to Furobufen and DBFA. Serum levels of DBFA in rats, dogs, and man increased in proportion to the oral dose. The t1/2 of Furobufen and DBFA in man did not appear to be altered by chronic treatment and were the same in both sexes. Furobufen and DBFA were strongly bound to human serum protein (greater than 99%). A method was elaborated to measure serum Furobufen and DBFA spectrophotofluorometrically in the presence of salicylates. Serum levels of Furobufen and DBFA were lower in rats treated with aspirin; the effect was dependent upon the dose of aspirin. At the doses used, aspirin did not affect serum Furobufen and DBFA in dogs and man.
Distribution and excretion of Furobufen in rats and dogs
Drug Metab Dispos 1981 Mar-Apr;9(2):125-8.PMID:6113110doi
Groups of male rats and dogs were given single doses of 50 mg of 14C-furobufen per kg orally or intravenously. In rats, tissue radioactivity levels were generally lower than that of serum. Radioactivity accumulated in and was retained by white adipose tissue. The radioactivity in fat was due to a conjugate of dibenzofuranacetic acid, the major metabolite of Furobufen. Approximately one-half of the dose was excreted each in the urine and feces of rats after oral and intravenous administration of 14C-furobufen. A similar excretion pattern was observed in dogs after an oral dose.